Publication date: Apr 12, 2019
Ovarian carcinomas are a group of distinct diseases classified by histotypes. As histotype-specific treatment evolves, accurate classification will become critical for optimal precision medicine approaches.
To uncover differences between the two most common histotypes – high-grade serous (HGSC) and endometrioid carcinoma (EC) – we performed label-free quantitative proteomics on freshly frozen tumour tissues (HGSC, n=10; EC, n=10). Eight candidate protein biomarkers specific to EC were validated by immunohistochemistry using tissue microarrays representing 361 cases of either EC or HGSC.
Over 500 proteins were differentially expressed (p
Postovit, L.M., Dieters-Castator, D.Z., Rambau, P.F., Kelemen, L.E., Siegers, G.M., Lajoie, G.A., and K”obel, M. Proteomics derived biomarker panel improves diagnostic precision to classify endometrioid and high-grade serous ovarian carcinoma. 04413. 2019 Clin Cancer Res.
- PMO Biomarker & Genetics Series: Most Important Advances in Precision Medicine
- Individualized metabolomics: opportunities and challenges.
- PMO Biomarker & Genetics Series: Oncologists and Pathologists
- Quantitative Dot Blot (QDB) as a universal platform for absolute quantification of tissue biomarkers.
- Molecular insights into cancer drug resistance from a proteomics perspective.
- TranscriptAchilles: a genome-wide platform to predict isoform biomarkers of gene essentiality in cancer.